Multipel sklerose: Forskelle mellem versioner

En række behandlinger, der måske kan begrænse anfald eller forbedre funktion er udforskes til stadighed. Nogle af disse behandlinger indebærer en kombination af medicin, der allerede bruges mod MS, såsom den samlede administrering af [[mitoxantron]] og [[glatirameracetat]] (''Copaxon'').<ref>[http://www.mxga-mstrial.co.uk United Kingdom early Mitoxantrone Copaxone trial.] Onyx Healthcare (2006-01-01). Hentet 2007-09-02.</ref> De fleste behandlingsmetoder, der allerede er i kliniske forsøg, involverer dog medikamenter, der bruges mod andre sygdomme. Disse er [[alemtuzumab]] (''Campath''),<ref>{{cite web|url=http://www.genzyme.com/corp/media/GENZ%20PR-050207.asp|title=Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN|publisher=Genzyme|date=07-02-01|accessdate=07-09-02}}</ref> [[daclizumab]] (''Zenapax''),<ref>{{cite web|url=http://www.pdl.com/index.cfm?navId=49|title=Daclizumab|publisher=PDL Biopharma|date=06-01-01|accessdate=07-09-02}}</ref> [[inosin]],<ref>{{cite web|url=http://www.clinicaltrials.gov/ct/show/NCT00067327|title=Treatment of Multiple Sclerosis Using Over the Counter Inosine|publisher=ClinicalTrials.gov|date=06-03-16|accessdate=07-09-02}}</ref> [[BG00012]],<ref>{{cite web|url=http://www.clinicaltrials.gov/ct2/show/NCT00420212?term=biogen&recr=Open&rank=12|title=Efficacy and Safety of BG00012 in Relapsing-Remitting Multiple Sclerosis|publisher=ClinicalTrials.gov|date=07-09-01|accessdate=07-11-12}}</ref> [[fingolimod]],<ref>{{cite web|url=http://www.clinicaltrials.gov/ct/show/NCT00289978|title=Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis|publisher=ClinicalTrials.gov|date=06-02-09|accessdate=07-09-02}}</ref> og [[teriflunomid]], den aktive metabolite af [[Sygdomsmodificerende lægemidler|DMARD]]en [[leflunomid]]. Alemtuzumab fungerede bedre end [[interferon beta-1a]] hvad angik at reducere funktionsnedsættelse i relapserende-remitterende MS, forestillingsabnormaliteter og hyppigheden af tilbagefald, med den bivirkning at de autoimmune problemer øgedes. Disse inkluderede tre tilfælde af [[ITP|idiopatisk trombocytopenisk purpura]], som førte til indstillingen af denne behandling.<ref name="pmid1234567">{{cite journal |author=The CAMMS223 Trial Investigators |title=Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis |journal=N Engl J Med |volume=359 |issue=17 |pages=1786–1801 |year=2008 |pmid=18946064 |doi= 10.1056/NEJMoa0802670}}</ref>

[[Lavdosis naltrexon]] er blevet ordineret "[[off-label-brug|off-label]]" mod visse autoimmune sygdomme, herunder MS, og der er anekdotisk bevis for dets nytte,<ref>{{cite journal |author=Agrawal YP |title=Low dose naltrexone therapy in multiple sclerosis |journal=Med. Hypotheses |volume=64 |issue=4 |pages=721–4 |year=2005 |pmid=15694688 |doi=10.1016/j.mehy.2004.09.024 }}</ref><ref>[http://clinicaltrials.gov/ct2/results?term=Low+dose+naltrexone+Multiple+Sclerosis search of clinicaltrials.gov data-base for Low dose naltrexone Multiple Sclerosis]</ref> men kun to små kliniske forsøg er blevet afholdt (per december 2008),<ref>[http://clinicaltrials.gov/ct2/show/NCT00501696?term=Low+dose+naltrexone+Multiple+Sclerosis&rank=1 2007 clinical trial using LDN]</ref> en af dem for primær progressiv MS.<ref name="pmid18728058">{{cite journal |author=Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G |title=A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. |journal=Multiple Sclerosis |volume=14 |issue=8 |pages=1076–83 |year=2008 |pmid=18728058 |doi=10.1177/1352458508095828 |last12=Cursi |first12=M |last13=Franchi |first13=S |last14=Martinelli |first14=V |last15=Nemni |first15=R |last16=Comi |first16=G |last17=Martino |first17=G}}</ref>